secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076833
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M
--------------------------------------------------------------------------------

- Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
- Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024
- Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients
- Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury
- Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/0001193125-26-076833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/revb-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer